NOVATO, Calif., March 30, 2026
Ultragenyx Pharmaceutical Inc. has announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for UX016, an innovative sialic acid prodrug therapy for the treatment of GNE myopathy (GNEM), a rare and debilitating neuromuscular disorder with no approved treatment options. This regulatory milestone enables the company to initiate a first-in-human Phase 1/2 clinical trial in the second half of 2026, marking a critical step forward in addressing a significant unmet need in rare genetic muscle diseases.
IND Clearance Unlocks Clinical Development Pathway
The FDA IND clearance for UX016 represents a pivotal advancement, allowing Ultragenyx to begin evaluating the therapy’s safety, pharmacokinetics, and efficacy in human patients. The planned Phase 1/2 study will enroll approximately 24 adult patients aged 18 to 55 years diagnosed with GNE myopathy, assessing outcomes such as muscle strength, functional performance, and patient-reported quality of life measures over a 48-week treatment period.
Notably, the program is supported through an innovative venture philanthropy funding model, demonstrating a collaborative approach between industry and patient advocacy groups to accelerate drug development in ultra-rare diseases. This strategy highlights a growing trend toward alternative funding mechanisms that prioritize patient-centric research and rapid clinical translation.
Novel Prodrug Design Enhances Muscle Targeting
Advertisement
UX016 is a next-generation small molecule prodrug composed of sialic acid (SA) linked to a hydrophobic fatty acid tail, designed to improve tissue distribution and cellular uptake, particularly in skeletal muscle. This advanced formulation addresses key limitations of earlier substrate replacement therapies by enabling enhanced delivery and sustained release of sialic acid within muscle cells, thereby restoring normal glycoprotein and glycolipid function.
Preclinical studies have demonstrated that UX016 can increase sialic acid levels across multiple muscle groups and restore them toward near-normal levels, suggesting its potential to slow or modify disease progression. By targeting the underlying metabolic deficiency in sialic acid biosynthesis, UX016 represents a precision medicine approach aimed at correcting the root cause of GNE myopathy rather than merely managing symptoms.
Addressing a Severe and Progressive Neuromuscular Disorder
GNE myopathy is a rare, inherited neuromuscular disease characterized by progressive muscle wasting, loss of mobility, and severe disability, often leading to patients becoming non-ambulatory and dependent on caregivers. The disease is caused by mutations in the GNE gene, resulting in impaired production of sialic acid, a critical molecule for maintaining muscle integrity and function.
Affecting approximately 10,000 individuals globally, GNEM remains an area of high unmet medical need, with no approved therapies currently available in the United States. The advancement of UX016 into clinical trials offers new hope for patients by introducing a targeted therapeutic strategy designed to restore biochemical balance and improve muscle function. Ultragenyx’s continued focus on rare and ultra-rare genetic disorders underscores its leadership in developing innovative therapies for underserved patient populations.
With FDA IND clearance achieved and clinical trials on the horizon, UX016 emerges as a promising candidate in the rare disease pipeline, combining novel drug design, precision targeting, and patient-centered development strategies to potentially transform the treatment landscape for GNE myopathy and related neuromuscular disorders.
Source: Ultragenyx Pharmaceutical Inc press release
